NBQX
Sign in to saveAlso known as 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline
NBQX (2,3-dioxo-6-nitro-7-sulfamoyl-benzo[f]quinoxaline) is an antagonist of the AMPA receptor.
Chemical data
- Formula
- C12H8N4O6S
- Molecular weight
- 336.28 g/mol
- IUPAC name
- 6-nitro-2,3-dioxo-1,4-dihydrobenzo[f]quinoxaline-7-sulfonamide
via PubChem
Research
1,770 papers- NBQX attenuates relapse of nicotine seeking but not nicotine and methamphetamine self-administration in rats.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry · 2021
- Structural and interaction analysis of human lipocalin-type prostaglandin D synthase with the poorly water-soluble drug NBQX.The FEBS journal · 2023
- NBQX attenuates excitotoxic injury in developing white matter.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2000
- NBQX blocks acute and late epileptogenic effects of perinatal hypoxia.Epilepsia · 1995
Article
2 sectionsContents
- See also
- References
NBQX (2,3-dioxo-6-nitro-7-sulfamoyl-benzo[f]quinoxaline) is an antagonist of the AMPA receptor.
NBQX blocks AMPA receptors in micromolar concentrations (~10–20 μM) and also blocks kainate receptors. In experiments, it is used to counter glutamate excitotoxicity. NBQX was found to have anticonvulsant activity in rodent seizure models.